Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-2: ARV-471 versus fulvestrant in ER-positive, HER2-negative advanced breast cancer
MOH_2023-04-27_012530Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing ARV-471 with fulvestrant (2 arms). Primary endpoint: Progression-free survival. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
vepdegestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-04-27_012530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-27_012530.